European Companies Search Engine
EU funding (€2,495,675): The next-generation heart pump to change patients’ lives and create a new standard of care Hor 14 Jul 2020 EU Research and Innovation programme "Horizon"
Overview
Text
The next-generation heart pump to change patients’ lives and create a new standard of care
Advanced heart failure (HF) is a deadly disease, with a booming incidence driven by durable socio-demographic trends. Left ventricular assist devices (LVADs) are a life-saving therapy for advanced HF patients and represent a billion-euro market. However, only 13% of the 60,000 eligible patients are implanted with current LVADs each year, due to the extremely high rate of severe adverse events (stroke, bleeding, infection) and the limited quality of life. CorWave is an innovative French SME created in 2011 with a mission to create a new standard of care for advanced HF patients. The company is developing a game-changing LVAD, which relies on a unique and patented breakthrough technology, the wave membrane. Unlike all current devices, which are continuous-flow rotary pumps, CorWave LVAD is a smart pump producing a physiologic and pulsatile blood flow, to restore a normal life to patients with minimal side effects. CorWave LVAD will cut in half severe complications and rehospitalisation costs. CorWave projects to take over 60% of the market and reach up to €1.1 billion of turnover in 2030, by taking advantage of the LVAD market structure, which is very favourable to new entrants (concentrated on a few centres), and by increasing the penetration rate. We have built a team of 50 experienced people, including world-class experts, and have gained a strong market traction. The clinical centres who support us through letters of intent are worth >25% of the European market. We partner with a network of industrial suppliers and have our own pilot production unit to manufacture prototypes that have proved successful in preclinical studies. Thanks to EIC Accelerator, CorWave will transform a very promising preclinical prototype (TRL 6-7) into an industrial CE-marked medical device (TRL 8-9) that patients, clinicians and payers are waiting for. EIC Accelerator would place CorWave on a trajectory to become a global medtech leader with an outstanding socioeconomic impact on the EU.
Funded Companies:
| Company name | Funding amount |
| Corwave | €2,495,675 |
Source: https://cordis.europa.eu/project/id/954151
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Corwave SA, Clichy, France.